Shahzad Aleena, Ur Rehman Anees, Naz Tehnia, Rasool Muhammad Fawad, Saeed Alisha, Rasheed Saba, Shakeel Sadia, Al-Tamimi Saleh Karamah, Hussain Rabia
Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
Dow College of Pharmacy, Dow University of Health Sciences, Karachi 74200, Pakistan.
Pharmacy (Basel). 2024 Dec 1;12(6):180. doi: 10.3390/pharmacy12060180.
: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes for cervical cancer patients treated with bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. This study aimed to assess the impact of bevacizumab on progression-free survival (PFS) and overall survival (OS) in patients with metastatic cervical cancer. : This systematic review was registered in PROSPERO (CRD42023456755). Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar identified 28 studies meeting the inclusion criteria. The outcomes of interest were PFS and OS. The statistical analysis computed hazard ratios (HRs) with 95% confidence intervals (CIs). The study also included a subgroup analysis by cervical cancer stage. : The pooled analysis revealed that bevacizumab-based therapy significantly improved both PFS with HR 0.77 (95% CI: 0.58-0.96; < 0.01; I = 58%) and OS with HR 0.63 (95% CI: 0.45-0.89; < 0.01; I = 41%) in cervical cancer patients. Subgroup analysis by stage of cervical cancer demonstrated better efficacy of bevacizumab in metastatic stage IVB cervical cancer patients indicated by HR for PFS (0.69, 95% CI: 0.54-0.79; < 0.01) and HR for OS (0.57, 95% CI: 0.46-0.73; < 0.01). : Bevacizumab exhibits a significant increase in PFS and OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer, particularly in stage IVB metastatic cervical cancer patients.
宫颈癌是女性癌症相关死亡的第三大主要原因。迄今为止，最成功的治疗方式之一是抑制血管内皮生长因子（VEGF）介导的血管生成。贝伐单抗是一种靶向VEGF-A的单克隆抗体。多项研究探讨了贝伐单抗联合铂类化疗治疗宫颈癌患者的疗效。本研究旨在评估贝伐单抗对转移性宫颈癌患者无进展生存期（PFS）和总生存期（OS）的影响。 本系统评价已在PROSPERO（CRD42023456755）注册。按照PRISMA指南，在PubMed和谷歌学术上进行全面的文献检索，确定了28项符合纳入标准的研究。关注的结果是PFS和OS。统计分析计算了风险比（HRs）及95%置信区间（CIs）。该研究还包括按宫颈癌分期进行的亚组分析。 汇总分析显示，基于贝伐单抗的治疗显著改善了宫颈癌患者的PFS（HR 0.77，95%CI：0.58 - 0.96；P < 0.01；I² = 58%）和OS（HR 0.63，95%CI：0.45 - 0.89；P < 0.01；I² = 41%）。按宫颈癌分期进行的亚组分析表明，贝伐单抗在IVB期转移性宫颈癌患者中疗效更佳，PFS的HR为（0.69，95%CI：0.54 - 0.79；P < 0.01），OS的HR为（0.57，95%CI：0.46 - 0.73；P < 0.01）。 贝伐单抗显著提高了PFS和OS，突出了抗血管生成疗法在宫颈癌中的疗效，尤其是在IVB期转移性宫颈癌患者中。
